Canine Atopic Dermatitis Treatment Market Analysis 2026

Current scenario of the canine atopic dermatitis market 

Key drivers of the Canine atopic dermatitis market 

• An increase in dog ownership is driving a market expansion.

Adoption of companion animals has increased, particularly dogs. Animals provide humans with unconditional love and have been shown to be emotionally, psychologically, and physically beneficial to their companions. These factors are the main causes of the increase in pet adoption. In these day of hectic schedules and nuclear families, taking care of a pet animal lessens feelings of loneliness and gives one's daily life a sense of fulfillment and purpose. Approximately 86.9 million US households, 66% own a dog, according to the American Pet Products Association's 2023-2024 National Pet Owners Survey.
https://www.americanpetproducts.org/news/News-Public-Relations/pet-industry-market-size-trends-ownership-statistics

In addition, the cost of maintaining dogs' health and going to the vet has gone up as more people own dogs. Since dogs are increasingly being diagnosed with several allergies, adopting a dog entail taking care of it. As a result, there is a considerable increase in the need for atopic dermatitis therapy in dogs. Environmental allergens can cause atopic dermatitis, a common allergy. The market is anticipated to develop as a result of the growing popularity of dogs and the rising cost of pet healthcare.

• Increasing global pollution driving market growth 

Due to their ability to permeate the skin, attach to the stratum corneum, and enter the systemic circulation, indoor and outdoor air pollutants have long been of interest in relation to the development of atopic dermatitis in dogs. According to the review paper by the MDPI, "Atopic Dermatitis in Domestic Animals: What Our Current Understanding Is and How This Applies to Clinical Practice," which was released in July 2021, animals can also get atopic dermatitis in a manner similar to that of humans.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310319/

According to the same source, the current circumstances of consuming processed foods instead of raw diets, increasing exposure to indoor environments and house dust mites, and decreasing exposure to beneficial bacteria may contribute to an increase in the development of clinical signs of atopic dermatitis. This is because pets were previously exposed to an outdoor environment with greater exposure to parasites and bacteria and less exposure to house dust mites. Over time, particulate pollution has increased. The average annual increase in particle pollution was 67.7% between 1998 and 2021.
https://aqli.epic.uchicago.edu/wp-content/uploads/2023/08/India-FactSheet-2023_Final.pdf

Because atopic dermatitis is a chronic condition that does not go away on its own, it is essential to manage the dog's environment and provide the right amount of medication. The global increase in pollution and the evolving human-like lifestyles of dogs are predicted to propel the market under study's expansion.

Restraints for the global Canine atopic dermatitis market

• Off-label drug usage restricting the market

Off-label drug use refers to the use of pharmaceuticals for indications that have not been authorized by the local regulatory body or the use of human medications for indications in animals. On the other hand, using off-label or extra-label medications can cause a number of serious health problems and have a detrimental impact on a dog's wellbeing. The practice of prescribing off-label medications has been approved by numerous authorities, which means that they can write a client a prescription or authorization to use a registered drug or veterinary chemical in violation of the approved label requirements. For example, veterinarians are allowed to give off-label medications in Australia. In certain situations, using veterinary chemicals that are off-label or unregistered is permissible under the Australian Pesticides and Veterinary Medicines Authority (APVMA) authorization or written instructions from a veterinarian.
https://agriculture.vic.gov.au/farm-management/chemicals/offlabel-chemical-use/offlabel-use-of-veterinary-chemicals#:~:text=Use%20of%20off%2Dlabel%20or,Veterinary%20Medicines%20Authority%20(APVMA).

The growth of the market under study is impacted by the availability of off-label medications prescribed by veterinarians, which puts non-related medications in competition with those sold in the canine atopic dermatitis market. Veterinarians therefore frequently utilize medications that are designated for animals, following a widespread practice. It offers a wide range of veterinarians from whom to select the medication for canine atopic dermatitis. Over the course of the projection period, this factor is anticipated to limit market growth.

Opportunities for the global Canine Atopic Dermatitis market

• Research & development spending is beneficial to the market.

The veterinary healthcare industry has experienced significant transformation in recent years due to the introduction of novel medications, therapies, and delivery systems for medications that have already received global approval. To grow the market, corporations never stop researching and developing new products. The results of a clinical study conducted in dogs with atopic dermatitis were published in April 2020 by Bioiberica Companion Animal Health and the University of Florida. The study confirmed the effectiveness of the Atopivet Spot-On topical formulation as a monotherapy or as part of a multimodal treatment to help restore skin barrier function, hydrate skin, and reduce itching.
https://www.bioiberica.com/en/media/news/companion-animal-health/clinical-trial-proves-efficacy-bioibericas-atopivet-spot-dogs-atopic-dermatitis

According to a November 2020 Wiley Online Library article, the clinical efficacy of a spray version of a veterinary product containing heat-killed lactobacilli (Lactobacillus rhamnosus and Lactobacillus reuteri) marketed as adjuvant therapy for allergic dogs on the clinical signs of canine atopic dermatitis was investigated. The aforementioned studies demonstrate how different regions of the world are placing a greater emphasis on new technology adoption and research in the fields of veterinary care and health. The companies' cooperation demonstrates their enthusiasm in market innovation. As a result, there is a huge window of opportunity for market expansion.
https://pubmed.ncbi.nlm.nih.gov/33245188/

Impact of COVID-19 on the Global Canine Atopic Dermatitis

The COVID-19 pandemic caused disruptions to the logistics of the delivery of several necessary pharmaceutical goods for pets as well as to veterinary disease research and development. For example, a study carried out in the United Kingdom, as reported in a Frontiers article from May 2022, indicated that a dog's diagnosis of a chronic illness decreased the likelihood that the dog would seek medical attention during the pandemic. This was reportedly because it was difficult to get care for non-urgent problems, and one major contributing factor was not having access to a veterinarian. As a result, the market under study was significantly impacted by the COVID-19 epidemic. However, the market under study is anticipated to reach its maximum potential over time due to a decline of COVID-19 instances and the relaxation of regulations.
https://www.frontiersin.org/articles/10.3389/fvets.2022.902219

The market for canine atopic dermatitis appears to have a promising future. In the upcoming years, it is projected that the market would benefit from the growing need for pet insurance as well as growing pet owner worry. Furthermore, the industry is expanding due to strict regulations implemented by the Food and Drug Administration (FDA) and other regulatory organizations to decrease the off-label use of human medications in animals.

Frequently Asked Questions (FAQs)